Skip to main content

Table 1 Demographic and clinical characteristics of groups

From: The miRNA 196a2 rs11614913 variant has prognostic impact on Turkish patients with multiple myeloma

   Patient group Control group
Median N:200 (%) N:200 (%)
Age    56 (28-82) 53 (22-68)
Gender Female/Male   91/109 (45.5/54.5) 99/101 (49.5/50.5)
Ig subtypes κ/λ   110/60 (64.7/35.3)  
  G/A   112/30 (65.2/17.4)  
  Light Chain   30 (17.4)  
Stages (Salmon-Durie) II/III   53/117 (31/69)  
  A/B   129/41 (76/24)  
ISS I   52 (30.4)  
  II/III   44/75 (25.7/43.9)  
ECOG >1   32/179 (17.9)  
Hemoglobin gr/dl 10.3 (5.9-15.5)   
White blood cell count /μl 6985 (5900-17,000)   
Platelet count 103/μl 170 (28-788)   
C-reactive protein mg/dl 8.8 (2.1-352)   
LDH IU/l 203 (93-1037)   
β2-microglobulin mg/l 5.0 (1.5-47)   
Albumin g/l 3.5 (1.6-5.1)   
Treatment VCd, OHKHT, Rd   156 (78)  
  VCd ± Rd   44 (22)  
Cytogenetic results (n:190) Normal (XX, XY)   179  
  13q   2  
  Monosomy (X, 14-22)   2  
  Hyper/diploidy   2 + 2  
  t (4;11)   1  
  t (4;14)   1  
  Trisomy 7   1  
OS (5 years)  %   71   
PFS (months)a   43.8   
Mortality    47 (26.5)  
Follow-up period a(month)   30 (4.8-155)   
  1. VCd Bortezomib, Cyclophosphamide, dexamethasone, Rd Lenolidomide, dexamethasone, AHSCT autologous hematopoeticstem cell transplantation, ECOG performance scores, Ig Immunglobulin, LDH Lactate dehydrogenase, ISS internationale stage system, OS overall survival, PFS Progression free survival
  2. amedian